| Year |
Citation |
Score |
| 2006 |
Bartlett N. Low temperature preparation and uses of potent oxidizers Journal of Fluorine Chemistry. 127: 1285-1288. DOI: 10.1016/J.Jfluchem.2006.05.021 |
0.36 |
|
| 2001 |
Casteel WJ, Lohmann DH, Bartlett N. Room temperature preparations of second and third transition series tetrafluorides and a possible novel structure type for OsF4 and RhF4 Journal of Fluorine Chemistry. 112: 165-171. DOI: 10.1016/S0022-1139(01)00507-3 |
0.328 |
|
| 2001 |
Dove MFA, Benki? P, Platte C, Richardson TJ, Bartlett N. Concerning the crystal structure of BrF3·AuF3 Journal of Fluorine Chemistry. 110: 83-86. DOI: 10.1016/S0022-1139(01)00414-6 |
0.593 |
|
| 2000 |
Graudejus O, Wilkinson AP, Chacón LC, Bartlett N. M-F interatomic distances and effective volumes of second and third transition series MF6- and MF6(2-) anions. Inorganic Chemistry. 39: 2794-800. PMID 11232815 DOI: 10.1021/Ic000041W |
0.351 |
|
| 1999 |
Shen C, Zemva B, Lucier GM, Graudejus O, Allman JA, Bartlett N. Disproportionation of Ag(II) to Ag(I) and Ag(III) in Fluoride Systems and Syntheses and Structures of (AgF(+))(2)AgF(4)(-)MF(6)(-) Salts (M = As, Sb, Pt, Au, Ru). Inorganic Chemistry. 38: 4570-4577. PMID 11671173 DOI: 10.1021/Ic9905603 |
0.387 |
|
| 1999 |
Graudejus O, Elder SH, Lucier GM, Shen C, Bartlett N. Room temperature syntheses of AuF6- and PtF6- salts, Ag+AuF6-, Ag2+PtF62-, and Ag2+pdF62-, and an estimate for E(MF6-) [M = Pt, Pd] Inorganic Chemistry. 38: 2503-2509. DOI: 10.1021/Ic981397Z |
0.314 |
|
| 1999 |
Shen C, Mayorga SG, Biagioni R, Piskoti C, Ishigami M, Zettl A, Bartlett N. Intercalation of Hexagonal Boron Nitride by Strong Oxidizers and Evidence for the Metallic Nature of the Products Ieee Journal of Solid-State Circuits. 147: 74-81. DOI: 10.1006/Jssc.1999.8176 |
0.353 |
|
| 1998 |
Lucier GM, Shen C, Elder SH, Bartlett N. Facile Routes to NiF(6)(2)(-), AgF(4)(-), AuF(6)(-), and PtF(6)(-) Salts Using O(2)(+) as a Source of O(2)F in Anhydrous HF. Inorganic Chemistry. 37: 3829-3834. PMID 11670486 DOI: 10.1021/Ic971603N |
0.305 |
|
| 1998 |
Whalen JM, Lucier GM, Chacón L, Bartlett N. The room temperature conversion of nickel difluoride to hexafluoronickelate(IV) salts of alkali cations Journal of Fluorine Chemistry. 88: 107-110. DOI: 10.1016/S0022-1139(98)00105-5 |
0.362 |
|
| 1998 |
Lucier GM, Whalen JM, Bartlett N. High yield room temperature syntheses of KAgF4 and AgF3 and the preparation and unit cell of LiAgF4 Journal of Fluorine Chemistry. 89: 101-104. DOI: 10.1016/S0022-1139(98)00093-1 |
0.36 |
|
| 1997 |
Elder SH, Lucier GM, Hollander FJ, Bartlett N. Synthesis Of Au(Ii) Fluoro Complexes And Their Structural And Magnetic Properties Journal of the American Chemical Society. 119: 1020-1026. DOI: 10.1021/Ja9630654 |
0.353 |
|
| 1995 |
Zemva B, Lutar K, Chacon L, Fele-Beuermann M, Allman J, Shen C, Bartlett N. Thermodynamically Unstable Fluorides of Nickel: NiF4 and NiF3 Syntheses and Some Properties Journal of the American Chemical Society. 117: 10025-10034. DOI: 10.1021/Ja00145A013 |
0.331 |
|
| 1993 |
Okino F, Bartlett N. Hexafluoroarsenates of graphite from its interaction with AsF5′ AsF5+ F2′ and O2AsF6′ and the structure of C14AsF6 Journal of the Chemical Society-Dalton Transactions. 2081-2090. DOI: 10.1039/Dt9930002081 |
0.335 |
|
| 1992 |
Casteel WJ, Wilkinson AP, Borrmann H, Serfass RE, Bartlett N. Preparation and structure of ruthenium tetrafluoride and a structural comparison with ruthenium trifluoride and ruthenium pentafluoride Inorganic Chemistry. 31: 3124-3131. DOI: 10.1021/Ic00040A024 |
0.331 |
|
| 1992 |
Lerner M, Hagiwara R, Bartlett N. Synthesis of main-group graphite fluoroanion salts with chlorine-assisted oxidation by Lewis-acid fluorides Journal of Fluorine Chemistry. 57: 1-13. DOI: 10.1016/S0022-1139(00)82811-0 |
0.582 |
|
| 1991 |
Zemva B, Lutar K, Jesih A, Casteel WJ, Wilkinson AP, Cox DE, Dreele RBV, Borrmann H, Bartlett N. Silver trifluoride: preparation, crystal structure, some properties, and comparison with AuF3 Journal of the American Chemical Society. 113: 4192-4198. DOI: 10.1021/Ja00011A021 |
0.335 |
|
| 1991 |
Z̆emva B, Lutar K, Casteel WJ, Bartlett N. Syntheses and some properties of binary fluorides of silver, copper and nickel Journal of Fluorine Chemistry. 54: 16. DOI: 10.1016/S0022-1139(00)83526-5 |
0.365 |
|
| 1990 |
Zemva B, Hagiwara R, Casteel WJ, Lutar K, Jesih A, Bartlett N. Spontaneous oxidation of xenon to Xe(II) by cationic Ag(II) in anhydrous hydrogen fluoride solutions Journal of the American Chemical Society. 112: 4846-4849. DOI: 10.1021/Ja00168A032 |
0.302 |
|
| 1989 |
Hagiwara R, Lerner M, Bartlett N. The preparation of planar-sheet graphite fluorides CxF with x < 2 Journal of the Chemical Society, Chemical Communications. 573-574. DOI: 10.1039/C39890000573 |
0.61 |
|
| 1989 |
Zemva B, Lutar K, Jesih A, Casteel WJ, Bartlett N. A general method for the synthesis of polymeric binary flurides exemplified by AgF3, NiF4, RuF4, and OsF4 Journal of the Chemical Society, Chemical Communications. 346-347. DOI: 10.1039/C39890000346 |
0.312 |
|
| 1989 |
Ẑemva B, Lutar K, Jesih A, Casteel WJ, Bartlett N. A low temperature route to binary fluorides exemplified by NiF4, AgF3, RuF4, OsF4 and ReF4 Journal of Fluorine Chemistry. 45: 30. DOI: 10.1016/S0022-1139(00)84405-X |
0.358 |
|
| 1988 |
Krishnan KM, Kouvetakis J, Sasaki T, Bartlett N. Characterization of Newly Synthesized Novel Graphite Films Mrs Proceedings. 121. DOI: 10.1557/Proc-121-527 |
0.539 |
|
| 1987 |
Žemva B, Jesih A, Templeton DH, Zalkin A, Cheetham AK, Bartlett N. Phases in the system XeF2/XeF5AsF6 and structural and vibrational evidence for the following ionization pathway: XeF2 → XeF+ + F- Journal of the American Chemical Society. 109: 7420-7427. DOI: 10.1021/Ja00258A028 |
0.302 |
|
| 1987 |
Bartlett N, Okino F, Rosenthal G, Mayorga S, Kourtakis K, Lerner M. Salts of graphite and boron nitride and related materials Synthetic Metals. 19: 981. DOI: 10.1016/0379-6779(87)90489-9 |
0.559 |
|
| 1986 |
Kouvetakis J, Kaner RB, Sattler ML, Bartlett N. A novel graphite-like material of composition BC3, and nitrogen–carbon graphites Journal of the Chemical Society, Chemical Communications. 1758-1759. DOI: 10.1039/C39860001758 |
0.599 |
|
| 1985 |
Mallouk T, Hawkins BL, Conrad MP, Zilm K, Maciel GE, Bartlett N. Raman, infrared and n.m.r. studies of the graphite hydrofluorides CxF1-δ(HF)δ(2 ≤ x ≤ 5) Philosophical Transactions - Royal Society. Mathematical, Physical and Engineering Sciences. 314: 179-187. DOI: 10.1098/Rsta.1985.0017 |
0.51 |
|
| 1985 |
Okino F, Bartlett N. Compositional, Structural, And Physical Studies Of Some Graphite Hexafluoroarsenates And Their Relatives Journal of Fluorine Chemistry. 29: 224. DOI: 10.1016/S0022-1139(00)83466-1 |
0.36 |
|
| 1984 |
Mallouk TE, Rosenthal GL, Mueller G, Brusasco R, Bartlett N. Fluoride ion affinities of germanium tetrafluoride and boron trifluoride from thermodynamic and structural data for (SF3)2GeF6, ClO2GeF5, and ClO2BF4 Inorganic Chemistry. 23: 3167-3173. DOI: 10.1021/Ic00188A028 |
0.464 |
|
| 1984 |
Mallouk TE, Desbat B, Bartlett N. Structural studies of salts of cis and trans .mu.-fluoro-bridged polymers of pentafluorogermanate(1-) and of the pentafluorogermanate(1-) monomer Inorganic Chemistry. 23: 3160-3166. DOI: 10.1021/Ic00188A027 |
0.453 |
|
| 1984 |
Rosenthal GL, Mallouk TE, Bartlett N. Intercalation of graphite by silicon tetrafluoride and fluorine to yield a second-stage salt C24SiF5 Synthetic Metals. 9: 433-440. DOI: 10.1016/0379-6779(84)90023-7 |
0.501 |
|
| 1983 |
Mallouk T, Bartlett N. Reversible intercalation of graphite by fluorine: a new bifluoride, C12HF2, and graphite fluorides, CxF (5 > x > 2) Journal of the Chemical Society, Chemical Communications. 103-105. DOI: 10.1039/C39830000103 |
0.498 |
|
| 1982 |
Mallouk T, Desbat B, Bartlett N. Structural, vibrational and thermodynamic studies of pentafluorogermanate salts Journal of Fluorine Chemistry. 21: 88. DOI: 10.1016/S0022-1139(00)85475-5 |
0.47 |
|
| 1982 |
Tötsch W, Bartlett N. Antimonypentafluoroorthotellurates: Sb(OTeF5)3, Sb(OTeF5)5 and salts of Sb(OTeF5)6− Journal of Fluorine Chemistry. 21: 32. DOI: 10.1016/S0022-1139(00)85374-9 |
0.336 |
|
| 1982 |
Rosenthal G, Okino F, Mallouk T, Bartlett N. New salts of graphite, C12+HF2− & C24+SiF5− and the treshold for the oxidative intercalation of graphite Journal of Fluorine Chemistry. 21: 26. DOI: 10.1016/S0022-1139(00)85362-2 |
0.493 |
|
| 1982 |
Okino F, Bartlett N. The relationship of graphite/AsF5 intercalation compounds to Cx+AsF6− salts Journal of Fluorine Chemistry. 21: 25. DOI: 10.1016/S0022-1139(00)85360-9 |
0.355 |
|
| 1982 |
Yeh S, Richardson TJ, Bartlett N. ReF7 and ReOF5 as fluoride ion donors Journal of Fluorine Chemistry. 21: 8. DOI: 10.1016/S0022-1139(00)85326-9 |
0.56 |
|
| 1982 |
Bartlett N. Stabilizing high-oxidation state cations Journal of Fluorine Chemistry. 21: 3. DOI: 10.1016/S0022-1139(00)85317-8 |
0.367 |
|
| 1980 |
McCarron EM, Grannec YJ, Bartlett N. Fluorogermanium(IV) salts of graphite. A system in equilibrium with elemental fluorine Journal of the Chemical Society, Chemical Communications. 1980: 890-891. DOI: 10.1039/C39800000890 |
0.317 |
|
| 1980 |
McQuillan B, Bartlett N, Mallouk T. The relationship between gas phase oxidation strengths and graphite intercalation reactions Synthetic Metals. 2: 213. DOI: 10.1016/0379-6779(80)90049-1 |
0.442 |
|
| 1978 |
Bartlett N, Biagioni RN, McQuillan BW, Robertson AS, Thompson AC. Novel salts of graphite and a boron nitride salt Journal of the Chemical Society, Chemical Communications. 200-201. DOI: 10.1039/C39780000200 |
0.341 |
|
| 1978 |
Zalkin A, Ward DL, Biagioni RN, Templeton DH, Bartlett N. Crystal structure of fluoroxenon(1+) hexafluoroarsenate(1-) Inorganic Chemistry. 17: 1318-1322. DOI: 10.1021/Ic50183A044 |
0.307 |
|
| 1978 |
Bartlett N, Biagioni RN, Mcquillan BW, Robertson AS, Thompson AC. Novel Salts Of Graphite And A Boron Nitride Salt Cheminform. 9. DOI: 10.1002/Chin.197826035 |
0.331 |
|
| 1977 |
Templeton LK, Templeton DH, Seppelt K, Bartlett N. Crystal and molecular structure of xenon bis(oxopentafluoroselenate(VI)), Xe(OSeF5)2 Cheminform. 8. DOI: 10.1002/Chin.197704003 |
0.315 |
|
| 1976 |
Templeton LK, Templeton DH, Bartlett N, Seppelt K. Crystal and molecular structure of uranium hexakis(oxopentafluorotellurate), U(OTeF5)6 Inorganic Chemistry. 15: 2720-2722. DOI: 10.1021/Ic50165A029 |
0.32 |
|
| 1976 |
Templeton LK, Templeton DH, Seppelt K, Bartlett N. Crystal and molecular structure of xenon bis(oxopentafluoroselenate(VI)), Xe(OSeF5)2 Inorganic Chemistry. 15: 2718-2720. DOI: 10.1021/Ic50165A028 |
0.357 |
|
| 1974 |
Richardson TJ, Bartlett N. Salts of hexafluorobenzene cation, C6F6+ Journal of the Chemical Society, Chemical Communications. 427-428. DOI: 10.1039/C39740000427 |
0.535 |
|
| 1974 |
Bartlett N, DeBoer BG, Hollander FJ, Sladky FO, Templeton DH, Zalkin A. Crystal structures of [trifluorodixenon(1+)][hexafluoroarsenate(1-)] and [pentafluorozenon (1+)][hexafluoroarsenate(1-)] Inorganic Chemistry. 13: 780-785. DOI: 10.1021/Ic50134A004 |
0.314 |
|
| 1974 |
Leary K, Zalkin A, Bartlett N. Crystal structure of .mu.-fluorodecafluorodixenon(1+) hexafluoroaurate(1-) and the Raman spectrum of .mu.-fluorodecafluorodixenon(1+) Inorganic Chemistry. 13: 775-779. DOI: 10.1021/Ic50134A003 |
0.3 |
|
| 1974 |
RICHARDSON TJ, BARTLETT N. ChemInform Abstract: SALTS OF HEXAFLUOROBENZENE CATION, C6F6(+) Chemischer Informationsdienst. 5: no-no. DOI: 10.1002/Chin.197434156 |
0.537 |
|
| 1973 |
Leary K, Zalkin A, Bartlett N. Crystal structure of [Xe2F11]+[AuF6] Journal of the Chemical Society, Chemical Communications. 131-132. DOI: 10.1039/C39730000131 |
0.339 |
|
| 1973 |
McKee DE, Adams CJ, Zalkin A, Bartlett N. Cations KrF+, XeOF3+, XeF3+, and XeOF5+ and oxidizing properties of KrF+ Journal of the Chemical Society, Chemical Communications. 26-28. DOI: 10.1039/C39730000026 |
0.306 |
|
| 1973 |
Morrell BK, Zalkin A, Tressaud A, Bartlett N. The Crystal Structure Of Rhodium Pentafluoride Inorganic Chemistry. 12: 2640-2644. DOI: 10.1021/Ic50129A029 |
0.505 |
|
| 1973 |
Leary K, Templeton DH, Zalkin A, Bartlett N. Crystal structure of [XeF5+]2[PdF62-] Inorganic Chemistry. 12: 1726-1730. DOI: 10.1021/Ic50126A004 |
0.307 |
|
| 1973 |
Bartlett N, Gennis M, Gibler DD, Morrell BK, Zalkin A. Crystal structures of [xenon fluoride(+)][ruthenium hexafluoride(-)] and [xenon pentafluoride(+)][ruthenium hexafluoride(-)] Inorganic Chemistry. 12: 1717-1721. DOI: 10.1021/Ic50126A002 |
0.328 |
|
| 1973 |
McKee DE, Zalkin A, Bartlett N. Crystal structure of [XeF3+] [Sb2F11-] Inorganic Chemistry. 12: 1713-1717. DOI: 10.1021/Ic50126A001 |
0.31 |
|
| 1973 |
Bartlett N, Gennis M, Gibler DD, Morrell BK, Zalkin A. Crystal Structures Of (Xef(+))(Ruf6(-)) And (Xef5(+))(Ruf6(-)) Cheminform. 4. DOI: 10.1002/Chin.197339014 |
0.31 |
|
| 1972 |
Leary K, Bartlett N. A new oxidation state of gold: the preparation and some properties of [AuF6]– salts Journal of the Chemical Society, Chemical Communications. 903-904. DOI: 10.1039/C39720000903 |
0.306 |
|
| 1972 |
Wechsberg M, Bulliner PA, Sladky FO, Mews R, Bartlett N. Fluorosulfates and perchlorates of xenon(II) and the salt [(FXeO)2S(O)F]+[AsF6]- Inorganic Chemistry. 11: 3063-3070. DOI: 10.1021/Ic50118A038 |
0.3 |
|
| 1972 |
Gibler DD, Adams CJ, Fischer M, Zalkin A, Bartlett N. Structural studies of trifluorosulfur(IV)yl, [SF3]+, salts including the crystal structure of [SF3]+[BF4]- Inorganic Chemistry. 11: 2325-2329. DOI: 10.1021/Ic50116A007 |
0.33 |
|
| 1972 |
Bartlett N, Wechsberg M, Jones GR, Burbank RD. Crystal structure of xenon(II) fluoride fluorosulfate, FXeOSO2F Inorganic Chemistry. 11: 1124-1127. DOI: 10.1021/Ic50111A042 |
0.311 |
|
| 1972 |
Leary K, Zalkin A, Bartlett N. THE CRYSTAL STRUCTURE OF Xe2F11+AuF6- AND THE RAMAN SPECTRUM OF Xe2F11+ Cheminform. 5. DOI: 10.1002/Chin.197422013 |
0.311 |
|
| 1971 |
Bartlett N, Wechsberg M. The Xenon Difluoride Complexes XeF2 · XeOF4; XeF2 · XeF6 · AsF5 and XeF2 · 2 XeF6 · 2 AsF5 and Their Relevance to Bond Polarity and Fluoride Ion Donor Ability of XeF2 and XeF6 Zeitschrift FüR Anorganische Und Allgemeine Chemie. 385: 5-17. DOI: 10.1002/Zaac.19713850103 |
0.32 |
|
| 1970 |
Jones GR, Burbank RD, Bartlett N. Crystal structure of the 1:1 molecular addition compound xenon difluoride-iodine pentafluoride, XeF2.IF5 Inorganic Chemistry. 9: 2264-2268. DOI: 10.1021/Ic50092A011 |
0.305 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 1986 |
Richardson TJ, Tanzella FL, Bartlett N. The Preparation And Characterization Of Radical-Cation Salts Derived From Perfluorobenzene, Perfluorotoluene And Perfluoronaphthalene Journal of the American Chemical Society. 108: 4937-4943. DOI: 10.1021/Ja00276A039 |
0.298 |
|
| 1973 |
McKee DE, Bartlett N. THE DIOXYGENYL SALTS 02+STbF6"" AND 02+Sb2F11- AND THEIR CONVENIENT LABORATORY SYNTHESES. Cheminform. 5. DOI: 10.1002/Chin.197401041 |
0.297 |
|
| 1973 |
McKee DE, Bartlett N. Dioxygenyl salts dioxygenylhexafluoroantimonate and dioxygenylundecafluorodiantimonate and their convenient laboratory syntheses Inorganic Chemistry. 12: 2738-2740. DOI: 10.1021/Ic50129A050 |
0.294 |
|
| 2002 |
Templeton LK, Templeton DH, Bartlett N, Seppelt K. Crystal And Molecular Structure Of Uranium Hexakis(Oxopentafluorotellurate), U(Otef5)6 Cheminform. 8. DOI: 10.1002/Chin.197704004 |
0.291 |
|
| 1977 |
Seppelt K, Bartlett N. Kernresonanzuntersuchungen an Hexafluoriden Zeitschrift FüR Anorganische Und Allgemeine Chemie. 436: 122-126. DOI: 10.1002/Zaac.19774360114 |
0.282 |
|
| 1973 |
Wechsberg M, Bulliner PA, Sladky FO, Mews R, Bartlett N. Fluorosulfate Und Perchlorate Von Xenon(Ii) Und Das Salz ((Fxeo)2S(O)F)(+)(Asf6)(-) Cheminform. 4. DOI: 10.1002/Chin.197307048 |
0.28 |
|
| 1973 |
McKee DE, Adams CJ, Bartlett N. Preparation and Raman spectra of the salts [XeF3+][SbF6-], [XeF3+][Sb2F11-], [XeOF3+][SbF6-] and [XeOF3+][Sb2F11-] Inorganic Chemistry. 12: 1722-1725. DOI: 10.1021/Ic50126A003 |
0.279 |
|
| 1989 |
Lutar K, Jesih A, Leban I, Zemva B, Bartlett N. Crystal structures of XeF sub 5 sup + MF sub 4 sup minus (M = Ag, Au) and their relevance to the basicity and oxidizability of MF sub 4 sup minus Inorganic Chemistry. 28: 3467-3471. DOI: 10.1021/Ic00317A014 |
0.278 |
|
| 1978 |
Adams CJ, Bartlett N. Tautomerism in Xenon Hexafluoride: An Investigation of Xenon Hexafluoride and its Complexes by Raman Spectroscopy† Israel Journal of Chemistry. 17: 114-125. DOI: 10.1002/Ijch.197800015 |
0.278 |
|
| 1998 |
Bartlett N. Relativistic effects and the chemistry of gold Gold Bulletin. 31: 22-25. DOI: 10.1007/Bf03215471 |
0.272 |
|
| 1992 |
Casteel WJ, Lucier G, Hagiwara R, Borrmann H, Bartlett N. Structural and magnetic properties of some AgF+ Salts Journal of Solid State Chemistry. 96: 84-96. DOI: 10.1016/S0022-4596(05)80300-7 |
0.27 |
|
| 1968 |
Bartlett N, Sladky FO. The relative fluoride ion donor abilities of XeF2, XeF4, and XeF6 and a chemical purification of XeF4 Journal of the American Chemical Society. 90: 5316-5317. DOI: 10.1021/Ja01021A072 |
0.26 |
|
| 1980 |
McCarron EM, Bartlett N. Composition and staging in the graphite–AsF6 system and its relationship to graphite–AsF5 Journal of the Chemical Society, Chemical Communications. 404-406. DOI: 10.1039/C39800000404 |
0.256 |
|
| 1987 |
Bartlett N. Fluorine: Oxidizer Par excellence Journal of Fluorine Chemistry. 35: 91. DOI: 10.1016/0022-1139(87)95069-X |
0.253 |
|
| 1998 |
Wang H, Ge P, Riordan CG, Brooker S, Woomer CG, Collins T, Melendres CA, Graudejus O, Bartlett N, Cramer SP. Integrated X-ray L Absorption Spectra. Counting Holes in Ni Complexes Journal of Physical Chemistry B. 102: 8343-8346. DOI: 10.1021/Jp9821026 |
0.246 |
|
| 1976 |
Bartlett N, Zemva B, Graham L. Redox Reactions In The Xenon Difluoride Platinum Fluoride And Xenon Difluoride Palladium Fluoride Systems And The Conversion Of Xenon Difluoride To Xenon Tetrafluoride And Xenon Cheminform. 7. DOI: 10.1002/Chin.197617037 |
0.245 |
|
| 1978 |
Adams CJ, Bartlett N. Tautomerism In Xenon Hexafluoride. An Investigation Of Xenon Hexafluoride And Its Complexes By Raman Spectroscopy Cheminform. 9. DOI: 10.1002/Chin.197839008 |
0.244 |
|
| 1972 |
Bartlett N, Wechsberg M, Jones GR, Burbank RD. Kristallstruktur Von Xenon(Ii)-Fluorid-Fluorosulfat, Fxeoso2F Cheminform. 3. DOI: 10.1002/Chin.197229013 |
0.213 |
|
| 1972 |
Gibler DD, Adams CJ, Fischer M, Zalkin A, Bartlett N. Strukturuntersuchungen Von Trifluorsulfuryl(Iv), (Sf3)(+)-Salzen Einschliesslich Der Kristallstruktur Von (Sf3)(+)(Bf4)(-) Cheminform. 3. DOI: 10.1002/Chin.197250010 |
0.212 |
|
| 2013 |
Dehdashti F, Laforest R, Gao F, Shoghi KI, Aft RL, Nussenbaum B, Kreisel FH, Bartlett NL, Cashen A, Wagner-Johnson N, MacH RH. Assessment of cellular proliferation in tumors by PET using 18F-ISO-1 Journal of Nuclear Medicine. 54: 350-357. PMID 23359657 DOI: 10.2967/Jnumed.112.111948 |
0.121 |
|
| 2010 |
Bartlett NC, Jankunas J, Zare RN, Harrison JA. Time-dependent depolarization of aligned D(2) caused by hyperfine coupling. Physical Chemistry Chemical Physics : Pccp. 12: 15689-94. PMID 20668756 DOI: 10.1039/C0Cp00518E |
0.12 |
|
| 2011 |
Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 52: 386-92. PMID 21321279 DOI: 10.2967/jnumed.110.082586 |
0.113 |
|
| 2012 |
Jankunas J, Bartlett NCM, Zare RN, Liu L, Xu X, Zhang DH. D+C(CH 3) 4 → HD (v′, j′)+C(CH 3) 3CH 2: Possible concerted flow of vibration energy into translation Molecular Physics. 110: 1713-1720. DOI: 10.1080/00268976.2012.673641 |
0.103 |
|
| 2015 |
Ogi Y, Obara Y, Katayama T, Suzuki YI, Liu SY, Bartlett NC, Kurahashi N, Karashima S, Togashi T, Inubushi Y, Ogawa K, Owada S, Rubešová M, Yabashi M, Misawa K, et al. Ultraviolet photochemical reaction of [Fe(III)(C2O4)3](3-) in aqueous solutions studied by femtosecond time-resolved X-ray absorption spectroscopy using an X-ray free electron laser. Structural Dynamics (Melville, N.Y.). 2: 034901. PMID 26798796 DOI: 10.1063/1.4918803 |
0.088 |
|
| 2014 |
Bartlett N, Gross L, Péron F, Asby DJ, Selby MD, Tavassoli A, Linclau B. Stereocontrol by quaternary centres: a stereoselective synthesis of (-)-luminacin D. Chemistry (Weinheim An Der Bergstrasse, Germany). 20: 3306-10. PMID 24519660 DOI: 10.1002/chem.201304776 |
0.085 |
|
| 2012 |
Kostakoglu L, Schöder H, Johnson JL, Hall NC, Schwartz LH, Straus DJ, LaCasce AS, Jung SH, Bartlett NL, Canellos GP, Cheson BD. Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? Leukemia & Lymphoma. 53: 2143-50. PMID 22421007 DOI: 10.3109/10428194.2012.676173 |
0.079 |
|
| 2011 |
Smeltzer JP, Cashen AF, Zhang Q, Homb A, Dehdashti F, Abboud CN, DiPersio JF, Stockerl-Goldstein KE, Uy GL, Vij R, Westervelt P, Bartlett NL, Fehniger TA. Prognostic significance of FDG-PET in relapsed or refractory classical hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation Biology of Blood and Marrow Transplantation. 17: 1646-1652. PMID 21601641 DOI: 10.1016/J.Bbmt.2011.04.011 |
0.064 |
|
| 2013 |
Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl BS, Friedberg JW, Blum KA, Habermann TM, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 684-91. PMID 23182987 DOI: 10.1200/JCO.2012.43.4803 |
0.062 |
|
| 2011 |
Straus DJ, Johnson JL, LaCasce AS, Bartlett NL, Kostakoglu L, Hsi ED, Schöder H, Hall NC, Jung SH, Canellos GP, Schwartz LH, Takvorian RW, Juweid ME, Cheson BD. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood. 117: 5314-20. PMID 21355087 DOI: 10.1182/blood-2010-10-314260 |
0.057 |
|
| 2015 |
Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Abramson JS, Petrich AM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, et al. Gray zone lymphoma with features intermediate between classical hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort. American Journal of Hematology. PMID 26044261 DOI: 10.1002/ajh.24082 |
0.056 |
|
| 2011 |
Bartlett NC, Jankunas J, Goswami T, Zare RN, Bouakline F, Althorpe SC. Differential cross sections for H + D2 → HD(v' = 2, j' = 0,3,6,9) + D at center-of-mass collision energies of 1.25, 1.61, and 1.97 eV. Physical Chemistry Chemical Physics : Pccp. 13: 8175-9. PMID 21170442 DOI: 10.1039/C0Cp02460K |
0.055 |
|
| 2018 |
Bartlett N. The Ones Who Struck Out: Positions: Asia Critique. 26: 423-449. DOI: 10.1215/10679847-6868225 |
0.053 |
|
| 2015 |
Advani RH, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl BS, Friedberg JW, Blum KA, Habermann TM, et al. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1936-42. PMID 25897153 DOI: 10.1200/JCO.2014.57.8138 |
0.052 |
|
| 2011 |
Bartlett NJ. Critical materials strategy for clean energy technologies Critical Materials Strategy For Clean Energy Technologies. 1-170. |
0.051 |
|
| 2011 |
Furman RR, Grossbard ML, Johnson JL, Pecora AL, Cassileth PA, Jung SH, Peterson BA, Nadler LM, Freedman A, Bayer RL, Bartlett NL, Hurd DD, Cheson BD. A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leukemia & Lymphoma. 52: 587-96. PMID 21275630 DOI: 10.3109/10428194.2010.543714 |
0.049 |
|
| 2012 |
Cheson BD, Bartlett NL, Vose JM, Lopez-Hernandez A, Seiz AL, Keating AT, Shamsili S, Papadopoulos KP. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer. 118: 3128-34. PMID 22006123 DOI: 10.1002/cncr.26510 |
0.047 |
|
| 2014 |
Advani RH, Horning SJ, Hoppe RT, Daadi S, Allen J, Natkunam Y, Bartlett NL. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma Journal of Clinical Oncology. 32: 912-918. PMID 24516013 DOI: 10.1200/JCO.2013.53.2069 |
0.046 |
|
| 2011 |
Nanua S, Bartlett NL, Hassan A, Robirds D, Branson J, Frater JL, Nguyen TT, Kreisel F. Composite diffuse large B-cell lymphoma and precursor B lymphoblastic lymphoma presenting as a double-hit lymphoma with MYC and BCL2 translocation. Journal of Clinical Pathology. 64: 1032-4. PMID 21778297 DOI: 10.1136/jclinpath-2011-200143 |
0.045 |
|
| 2015 |
Fayad L, Ansell SM, Advani R, Coiffier B, Stuart R, Bartlett NL, Forero-Torres A, Kuliczkowski K, Belada D, Ng E, Drachman JG. Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Leukemia & Lymphoma. 56: 2569-78. PMID 25651427 DOI: 10.3109/10428194.2015.1007504 |
0.044 |
|
| 2014 |
Wang M, Popplewell LL, Collins RH, Winter JN, Goy A, Kaminski MS, Bartlett NL, Johnston PB, Lister J, Fanning SR, Tuscano JM, Beck JT, Kaya H, Robeva A, Fan J, et al. Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. British Journal of Haematology. 165: 510-8. PMID 24579926 DOI: 10.1111/bjh.12780 |
0.044 |
|
| 2012 |
Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2190-6. PMID 22614995 DOI: 10.1200/JCO.2011.38.0402 |
0.043 |
|
| 2011 |
Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, Schneider SE, Keppel CR, Wagner-Johnston ND, Carson KR, Bartlett NL. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood. 118: 5119-25. PMID 21937701 DOI: 10.1182/Blood.V114.22.3693.3693 |
0.042 |
|
| 2015 |
Carson KR, Riedell P, Lynch R, Nabhan C, Wildes TM, Liu W, Ganti A, Roop R, Sanfilippo KM, O'Brian K, Liu J, Bartlett NL, Cashen A, Wagner-Johnston N, Fehniger TA, et al. Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma Journal of Geriatric Oncology. 6: 211-218. DOI: 10.1016/j.jgo.2015.01.003 |
0.042 |
|
| 2015 |
Leonard JP, Jung SH, Johnson J, Pitcher BN, Bartlett NL, Blum KA, Czuczman M, Giguere JK, Cheson BD. Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26304886 DOI: 10.1200/Jco.2014.59.9258 |
0.041 |
|
| 2015 |
Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL, Crump M, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Stewart DA, Kahl BS, Friedberg JW, Blum KA, et al. Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. British Journal of Haematology. PMID 26343802 DOI: 10.1111/bjh.13634 |
0.041 |
|
| 2015 |
Rashidi A, Oak E, Carson KR, Wagner-Johnston ND, Kreisel F, Bartlett NL. Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria. Leukemia & Lymphoma. 1-3. PMID 26397936 DOI: 10.3109/10428194.2015.1096356 |
0.04 |
|
| 2014 |
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, et al. Non-Hodgkin's lymphomas, version 4.2014. Journal of the National Comprehensive Cancer Network : Jnccn. 12: 1282-303. PMID 25190696 DOI: 10.6004/Jnccn.2014.0125 |
0.04 |
|
| 2016 |
Rashidi A, Bartlett NL. Radiation for early-stage nodular lymphocyte-predominant Hodgkin lymphoma: A double-edged sword? Leukemia and Lymphoma. 57: 249-251. DOI: 10.3109/10428194.2015.1115045 |
0.04 |
|
| 2013 |
Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Gospodarowicz M, Cheson BD, Stiff PJ, Advani R, Miller TP, Hoppe RT, Kahl BS, et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. British Journal of Haematology. 161: 76-86. PMID 23356491 DOI: 10.1111/bjh.12222 |
0.04 |
|
| 2012 |
Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2183-9. PMID 22454421 DOI: 10.1200/JCO.2011.38.0410 |
0.039 |
|
| 2015 |
Carson KR, Riedell P, Lynch R, Nabhan C, Wildes TM, Liu W, Ganti A, Roop R, Sanfilippo KM, O'Brian K, Liu J, Bartlett NL, Cashen A, Wagner-Johnston N, Fehniger TA, et al. Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. Journal of Geriatric Oncology. 6: 211-8. PMID 25614297 DOI: 10.1016/J.Jgo.2015.01.003 |
0.039 |
|
| 2015 |
Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith SM, Kahl BS, Bartlett NL, et al. Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 2399-404. PMID 26077240 DOI: 10.1200/JCO.2014.60.6327 |
0.039 |
|
| 2013 |
Smith SM, Schöder H, Johnson JL, Jung SH, Bartlett NL, Cheson BD. The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). Leukemia & Lymphoma. 54: 1405-10. PMID 23194022 DOI: 10.3109/10428194.2012.744453 |
0.038 |
|
| 2015 |
Morrison VA, Jung SH, Johnson J, LaCasce A, Blum KA, Bartlett NL, Pitcher BN, Cheson BD. Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). Leukemia & Lymphoma. 56: 958-64. PMID 24996441 DOI: 10.3109/10428194.2014.938333 |
0.038 |
|
| 2015 |
Morrison VA, Jung SH, Johnson J, Lacasce A, Blum KA, Bartlett NL, Pitcher BN, Cheson BD. Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: Final results of a phase II trial (CALGB 50501) Leukemia and Lymphoma. 56: 958-964. DOI: 10.3109/10428194.2014.938333 |
0.038 |
|
| 2015 |
Singanayagam A, Glanville N, Walton RP, Aniscenko J, Pearson RM, Pinkerton JW, Horvat JC, Hansbro PM, Bartlett NW, Johnston SL. A short-term mouse model that reproduces the immunopathological features of rhinovirus-induced exacerbation of COPD. Clinical Science (London, England : 1979). 129: 245-58. PMID 25783022 DOI: 10.1042/CS20140654 |
0.037 |
|
| 2013 |
Scott DW, Chan FC, Hong F, Rogic S, Tan KL, Meissner B, Ben-Neriah S, Boyle M, Kridel R, Telenius A, Woolcock BW, Farinha P, Fisher RI, Rimsza LM, Bartlett NL, et al. Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 692-700. PMID 23182984 DOI: 10.1200/JCO.2012.43.4589 |
0.037 |
|
| 2014 |
Wildes TM, Farrington L, Yeung C, Harrington AM, Foyil KV, Liu J, Kreisel F, Bartlett NL, Fenske TS. Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers. Therapeutic Advances in Hematology. 5: 3-12. PMID 24490019 DOI: 10.1177/2040620713514682 |
0.037 |
|
| 2014 |
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, et al. Non-Hodgkin's lymphomas, version 2.2014. Journal of the National Comprehensive Cancer Network : Jnccn. 12: 916-46. PMID 24925202 DOI: 10.6004/Jnccn.2014.0086 |
0.036 |
|
| 2012 |
Foss F, Horwitz SM, Coiffier B, Bartlett N, Popplewell L, Pro B, Pinter-Brown LC, Shustov A, Furman RR, Haioun C, Koutsoukos T, O'Connor OA. Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: A subgroup efficacy analysis from the PROPEL study Clinical Lymphoma, Myeloma and Leukemia. 12: 238-243. PMID 22542448 DOI: 10.1016/J.Clml.2012.01.010 |
0.036 |
|
| 2014 |
de Vos S, Forero-Torres A, Ansell SM, Kahl B, Cheson BD, Bartlett NL, Furman RR, Winter JN, Kaplan H, Timmerman J, Whiting NC, Drachman JG, Advani R. A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. Journal of Hematology & Oncology. 7: 44. PMID 24919462 DOI: 10.1186/1756-8722-7-44 |
0.036 |
|
| 2013 |
Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, et al. Non-Hodgkin's lymphomas, version 1.2013. Journal of the National Comprehensive Cancer Network : Jnccn. 11: 257-72; quiz 273. PMID 23486452 DOI: 10.6004/Jnccn.2013.0037 |
0.035 |
|
| 2019 |
Leblanc D, Bartlett N, Lynch-Hill Y, Macneil M, Goodall B, Oldford S, Barrett L. FRI-238-Shifty business: Task shifting is essential to sustained increases in hepatitis C care engagement Journal of Hepatology. 70: e499. DOI: 10.1016/S0618-8278(19)30983-1 |
0.034 |
|
| 2012 |
Carson KR, Bartlett NL, McDonald JR, Luo S, Zeringue A, Liu J, Fu Q, Chang SH, Colditz GA. Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma Journal of Clinical Oncology. 30: 3217-3222. PMID 22649138 DOI: 10.1200/JCO.2011.39.2100 |
0.032 |
|
| 2013 |
Traub S, Nikonova A, Carruthers A, Dunmore R, Vousden KA, Gogsadze L, Hao W, Zhu Q, Bernard K, Zhu J, Dymond M, McLean GR, Walton RP, Glanville N, Humbles A, ... ... Bartlett NW, et al. An Anti-Human ICAM-1 Antibody Inhibits Rhinovirus-Induced Exacerbations of Lung Inflammation Plos Pathogens. 9. PMID 23935498 DOI: 10.1371/journal.ppat.1003520 |
0.032 |
|
| 2015 |
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hoppe RT, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 326-62. PMID 25736010 DOI: 10.6004/Jnccn.2015.0045 |
0.032 |
|
| 2011 |
Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, et al. Non-Hodgkin's lymphomas. Journal of the National Comprehensive Cancer Network : Jnccn. 9: 484-560. PMID 21550968 DOI: 10.6004/Jnccn.2011.0046 |
0.032 |
|
| 2012 |
Forero-Torres A, Fanale M, Advani R, Bartlett NL, Rosenblatt JD, Kennedy DA, Younes A. Brentuximab vedotin in transplant-naïve patients with relapsed or refractory Hodgkin lymphoma: Analysis of two phase I studies Oncologist. 17: 1073-1080. PMID 22855426 DOI: 10.1634/theoncologist.2012-0133 |
0.032 |
|
| 2015 |
Flinn IW, Bartlett NL, Blum KA, Ardeshna KM, LaCasce AS, Flowers CR, Shustov AR, Thress KS, Mitchell P, Zheng F, Skolnik JM, Friedberg JW. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). European Journal of Cancer (Oxford, England : 1990). 54: 11-17. PMID 26707592 DOI: 10.1016/j.ejca.2015.10.005 |
0.032 |
|
| 2013 |
Feyerer M, Kruk D, Bartlett N, Rodney K, McKenzie C, Green P, Keller L, Adcroft P. The Lunch Bunch: an innovative strategy to combat depression and delirium through socialization in elderly sub-acute medicine patients. Nursing Leadership (Toronto, Ont.). 26: 43-51. PMID 24860951 |
0.032 |
|
| 2015 |
Evens AM, Balasubramanian S, Vose JM, Harb W, Gordon LI, Langdon R, Sprague J, Sirisawad M, Mani C, Yue J, Luan Y, Horton S, Graef T, Bartlett NL. A phase I/II multicenter, open-label study of the oral histone deacetylase inhibitor abexinostat in relapsed/refractory lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26482040 DOI: 10.1158/1078-0432.CCR-15-0624 |
0.031 |
|
| 2011 |
Bartlett NC, Jankunas J, Zare RN. False estimates of stimulated Raman pumping efficiency caused by the optical Stark effect. The Journal of Chemical Physics. 134: 234310. PMID 21702559 DOI: 10.1063/1.3601923 |
0.031 |
|
| 2015 |
Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, Bello CM, Spitzer G, Palanca-Wessels MC, Kennedy DA, Levine P, Yang J, Bartlett NL. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 125: 1394-402. PMID 25573987 DOI: 10.1182/blood-2014-09-598763 |
0.031 |
|
| 2013 |
Evens AM, Advani R, Press OW, Lossos IS, Vose JM, Hernandez-Ilizaliturri FJ, Robinson BK, Otis S, Nadav Dagan L, Abdallah R, Kroll-Desrosiers A, Yarber JL, Sandoval J, Foyil K, Parker LM, ... ... Bartlett NL, et al. Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 4132-9. PMID 24043736 DOI: 10.1200/Jco.2013.49.8220 |
0.03 |
|
| 2014 |
Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O'Connor OA, Siddiqi T, Kennedy DA, Oki Y. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 123: 3095-100. PMID 24652992 DOI: 10.1182/blood-2013-12-542142 |
0.03 |
|
| 2013 |
Bartlett NL. Limited-stage Hodgkin lymphoma: optimal chemotherapy and the role of radiotherapy. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. 374-80. PMID 23714551 DOI: 10.1200/EdBook_AM.2013.33.374 |
0.029 |
|
| 2014 |
Hong F, Habermann TM, Gordon LI, Hochster H, Gascoyne RD, Morrison VA, Fisher RI, Bartlett NL, Stiff PJ, Cheson BD, Crump M, Horning SJ, Kahl BS. The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 669-74. PMID 24567515 DOI: 10.1093/annonc/mdt594 |
0.029 |
|
| 2012 |
Horwitz SM, Kim YH, Foss F, Zain JM, Myskowski PL, Lechowicz MJ, Fisher DC, Shustov AR, Bartlett NL, Delioukina ML, Koutsoukos T, Saunders ME, O'Connor OA, Duvic M. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 119: 4115-22. PMID 22394596 DOI: 10.1182/Blood-2011-11-390211 |
0.029 |
|
| 2011 |
O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1182-9. PMID 21245435 DOI: 10.1200/JCO.2010.29.9024 |
0.028 |
|
| 2013 |
Forero-Torres A, Bartlett N, Beaven A, Myint H, Nasta S, Northfelt DW, Whiting NC, Drachman JG, Lobuglio AF, Moskowitz CH. Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma Leukemia and Lymphoma. 54: 277-283. PMID 22775314 DOI: 10.3109/10428194.2012.710328 |
0.028 |
|
| 2014 |
May J, Carson KR, Butler S, Liu W, Bartlett NL, Wagner-Johnston ND. High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis. Leukemia & Lymphoma. 55: 1345-9. PMID 24004183 DOI: 10.3109/10428194.2013.840780 |
0.027 |
|
| 2015 |
Bartlett NW, Tolley MT, Overvelde JT, Weaver JC, Mosadegh B, Bertoldi K, Whitesides GM, Wood RJ. SOFT ROBOTICS. A 3D-printed, functionally graded soft robot powered by combustion. Science (New York, N.Y.). 349: 161-5. PMID 26160940 DOI: 10.1126/Science.Aab0129 |
0.027 |
|
| 2012 |
Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL, Advani RH, Buckstein R, Rimsza LM, Connors JM, Steidl C, Gordon LI, Horning SJ, Gascoyne RD. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood. 120: 3280-7. PMID 22948049 DOI: 10.1182/blood-2012-04-421057 |
0.026 |
|
| 2012 |
Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad L, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, et al. Non-Hodgkin's Lymphomas, version 3.2012. Journal of the National Comprehensive Cancer Network : Jnccn. 10: 1487-98. PMID 23221787 DOI: 10.6004/Jnccn.2012.0155 |
0.026 |
|
| 2015 |
Wagner-Johnston ND, Link BK, Byrtek M, Dawson KL, Hainsworth J, Flowers CR, Friedberg JW, Bartlett NL. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood. 126: 851-7. PMID 26105149 DOI: 10.1182/blood-2015-01-621375 |
0.026 |
|
| 2011 |
Acton JH, Bartlett NS, Greenstein VC. Comparing the Nidek MP-1 and Humphrey field analyzer in normal subjects. Optometry and Vision Science : Official Publication of the American Academy of Optometry. 88: 1288-97. PMID 21822159 DOI: 10.1097/Opx.0B013E31822B3746 |
0.025 |
|
| 2012 |
Welch JS, Foyil KV, Powers ML, Middleton WD, Bartlett NL. Solid, low-attenuation splenic lesions on computed tomography in patients with indolent lymphoma often signal transformation: a series of ten patients. Clinical Lymphoma, Myeloma & Leukemia. 12: 452-4. PMID 22981965 DOI: 10.1016/j.clml.2012.08.001 |
0.025 |
|
| 2013 |
Glanville N, McLean GR, Guy B, Lecouturier V, Berry C, Girerd Y, Gregoire C, Walton RP, Pearson RM, Kebadze T, Burdin N, Bartlett NW, Almond JW, Johnston SL. Cross-serotype immunity induced by immunization with a conserved rhinovirus capsid protein. Plos Pathogens. 9: e1003669. PMID 24086140 DOI: 10.1371/journal.ppat.1003669 |
0.024 |
|
| 2015 |
Oak E, Bartlett NL. Blinatumomab for the treatment of B-cell lymphoma. Expert Opinion On Investigational Drugs. 24: 715-24. PMID 25739952 DOI: 10.1517/13543784.2015.1021415 |
0.024 |
|
| 2015 |
Oak E, Bartlett NL. Blinatumomab for the treatment of B-cell lymphoma Expert Opinion On Investigational Drugs. 24: 715-724. DOI: 10.1517/13543784.2015.1021415 |
0.024 |
|
| 2014 |
Gopal AK, Bartlett NL, Forero-Torres A, Younes A, Chen R, Friedberg JW, Matous JV, Shustov AR, Smith SE, Zain J, O'Meara MM, Fanale MA. Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leukemia & Lymphoma. 55: 2328-34. PMID 24359243 DOI: 10.3109/10428194.2013.876496 |
0.024 |
|
| 2014 |
Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Huebner D, Kennedy DA, Shustov AR. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3137-43. PMID 25135998 DOI: 10.1200/JCO.2013.54.2456 |
0.024 |
|
| 2015 |
Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. The Lancet. Oncology. PMID 26655421 DOI: 10.1016/S1470-2045(15)00465-9 |
0.024 |
|
| 2015 |
Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. The New England Journal of Medicine. PMID 26639149 DOI: 10.1056/NEJMoa1509388 |
0.023 |
|
| 2015 |
Bartlett NCM, Ogi Y, Suzuki T. Ultrafast photoelectron imaging using tunable UV and vacuum UV pulses Chemistry Letters. 44: 791-793. DOI: 10.1246/cl.150177 |
0.022 |
|
| 2013 |
Collison A, Hatchwell L, Verrills N, Wark PA, de Siqueira AP, Tooze M, Carpenter H, Don AS, Morris JC, Zimmermann N, Bartlett NW, Rothenberg ME, Johnston SL, Foster PS, Mattes J. The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity. Nature Medicine. 19: 232-7. PMID 23334847 DOI: 10.1038/nm.3049 |
0.021 |
|
| 2015 |
Rashidi A, Bartlett NL. Biologic agents in the management of Hodgkin lymphoma. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 587-96. PMID 25964642 |
0.021 |
|
| 2013 |
Cashen AF, Christian BA, Bartlett NL. Therapy in primary mediastinal B-cell lymphoma. The New England Journal of Medicine. 369: 282-3. PMID 23863061 DOI: 10.1056/NEJMc1305983#SA2 |
0.021 |
|
| 2012 |
Wagner-Johnston ND, Bartlett NL, Cashen A, Berger JR. Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin Leukemia and Lymphoma. 53: 2283-2286. PMID 22424602 DOI: 10.3109/10428194.2012.676170 |
0.02 |
|
| 2015 |
Rosario M, Liu B, Kong L, Collins L, Schneider SE, Chen X, Han KP, Jeng EK, Rhode PR, Leong JW, Schappe T, Jewell B, Keppel CR, Shah K, Hess B, ... ... Bartlett NL, et al. The IL-15-based ALT-803 complex enhances FcγRIIIa-triggered NK cell responses and in vivo clearance of B cell lymphomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26423796 DOI: 10.1158/1078-0432.Ccr-15-1419 |
0.019 |
|
| 2013 |
Kanakry JA, Li H, Gellert LL, Lemas MV, Hsieh WS, Hong F, Tan KL, Gascoyne RD, Gordon LI, Fisher RI, Bartlett NL, Stiff P, Cheson BD, Advani R, Miller TP, et al. Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood. 121: 3547-53. PMID 23386127 DOI: 10.1182/Blood-2012-09-454694 |
0.019 |
|
| 2014 |
Pingali SR, Jewell SW, Havlat L, Bast MA, Thompson JR, Eastwood DC, Bartlett NL, Armitage JO, Wagner-Johnston ND, Vose JM, Fenske TS. Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission. Cancer. 120: 2122-9. PMID 24711253 DOI: 10.1002/cncr.28698 |
0.019 |
|
| 2011 |
Bartlett N, Wood F. Deplump for streaming data Data Compression Conference Proceedings. 363-372. DOI: 10.1109/DCC.2011.43 |
0.019 |
|
| 2012 |
Bartlett NW, Slater L, Glanville N, Haas JJ, Caramori G, Casolari P, Clarke DL, Message SD, Aniscenko J, Kebadze T, Zhu J, Mallia P, Mizgerd JP, Belvisi M, Papi A, et al. Defining critical roles for NF-κB p65 and type I interferon in innate immunity to rhinovirus. Embo Molecular Medicine. 4: 1244-60. PMID 23165884 DOI: 10.1002/Emmm.201201650 |
0.019 |
|
| 2014 |
Jayaraman A, Jackson DJ, Message SD, Pearson RM, Aniscenko J, Caramori G, Mallia P, Papi A, Shamji B, Edwards M, Westwick J, Hansel T, Stanciu LA, Johnston SL, Bartlett NW. IL-15 complexes induce NK- and T-cell responses independent of type I IFN signaling during rhinovirus infection. Mucosal Immunology. 7: 1151-64. PMID 24472849 DOI: 10.1038/mi.2014.2 |
0.018 |
|
| 2012 |
Bartlett NL. Advances in LLM: Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. Clinical Advances in Hematology & Oncology : H&O. 10: 468-71. PMID 22895289 |
0.018 |
|
| 2010 |
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas New England Journal of Medicine. 363: 1812-1821. PMID 21047225 DOI: 10.1056/NEJMoa1002965 |
0.018 |
|
| 2012 |
Smith K, Bartlett N, Wang N. A harm reduction paradox: Comparing China's policies on needle and syringe exchange and methadone maintenance International Journal of Drug Policy. 23: 327-332. PMID 22377341 DOI: 10.1016/J.Drugpo.2011.09.010 |
0.018 |
|
| 2005 |
Hammett TM, Bartlett NA, Chen Y, Ngu D, Cuong DD, Phuong NM, Tho NH, Van LK, Liu W, Donghua M, Shaomi X, Chen H, Quyen HN, Broadhead RS, Des Jarlais DC. Law enforcement influences on HIV prevention for injection drug users: Observations from a cross-border project in China and Vietnam International Journal of Drug Policy. 16: 235-245. DOI: 10.1016/j.drugpo.2005.05.009 |
0.018 |
|
| 2012 |
Foyil KV, Kennedy DA, Grove LE, Bartlett NL, Cashen AF. Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma. Leukemia & Lymphoma. 53: 506-7. PMID 21867368 DOI: 10.3109/10428194.2011.614706 |
0.017 |
|
| 2011 |
VanderLaan DP, Gothreau LM, Bartlett NH, Vasey PL. Separation anxiety in feminine boys: Pathological or prosocial? Journal of Gay and Lesbian Mental Health. 15: 30-45. DOI: 10.1080/19359705.2011.530570 |
0.017 |
|
| 2015 |
Nguyen TT, Frater JL, Klein J, Chen L, Bartlett NL, Foyil KV, Kreisel FH. Expression of TIA1 and PAX5 in Classical Hodgkin Lymphoma at Initial Diagnosis May Predict Clinical Outcome. Applied Immunohistochemistry & Molecular Morphology : Aimm / Official Publication of the Society For Applied Immunohistochemistry. PMID 26067141 DOI: 10.1097/PAI.0000000000000200 |
0.017 |
|
| 2014 |
Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, Advani R, Matous JV, Ramchandren R, Rosenblatt JD, Huebner D, Levine P, Grove L, Forero-Torres A. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. Journal of Hematology & Oncology. 7: 24. PMID 24642247 DOI: 10.1186/1756-8722-7-24 |
0.017 |
|
| 2015 |
Rashidi A, Oak E, Bartlett NL. Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma. Blood. 125: 3354-5. PMID 25999445 DOI: 10.1182/blood-2015-02-628362 |
0.017 |
|
| 2011 |
Vanderlaan DP, Gothreau LM, Bartlett NH, Vasey PL. Recalled separation anxiety and gender atypicality in childhood: a study of Canadian heterosexual and homosexual men and women. Archives of Sexual Behavior. 40: 1233-40. PMID 21063904 DOI: 10.1007/S10508-010-9695-Z |
0.017 |
|
| 2013 |
McLean GR, Walton RP, Shetty S, Peel TJ, Paktiawal N, Kebadze T, Gogsadze L, Niespodziana K, Valenta R, Bartlett NW, Johnston SL. Corrigendum to: "Rhinovirus infections and immunisation induce cross-serotype reactive antibodies to VP1" [Antiviral Res. 95(3) (2012) 193-201] Antiviral Research. 97: 381. DOI: 10.1016/j.antiviral.2013.02.004 |
0.017 |
|
| 2012 |
McLean GR, Walton RP, Shetty S, Paktiawal N, Kebadze T, Gogsadze L, Niespodziana K, Valenta R, Bartlett NW, Johnston SL. Rhinovirus infections and immunisation induce cross-serotype reactive antibodies to VP1 Antiviral Research. 95: 193-201. PMID 22742898 DOI: 10.1016/j.antiviral.2012.06.006 |
0.017 |
|
| 2013 |
Bartlett NL, Foyil KV. Hodgkin Lymphoma Abeloff's Clinical Oncology: Fifth Edition. 2018-2032.e4. DOI: 10.1016/B978-1-4557-2865-7.00105-3 |
0.016 |
|
| 2013 |
Brignull LM, Czimmerer Z, Saidi H, Daniel B, Villela I, Bartlett NW, Johnston SL, Meira LB, Nagy L, Nohturfft A. Reprogramming of lysosomal gene expression by interleukin-4 and Stat6. Bmc Genomics. 14: 853. PMID 24314139 DOI: 10.1186/1471-2164-14-853 |
0.016 |
|
| 2012 |
Foyil KV, Bartlett NL. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma Cancer Journal (United States). 18: 450-456. PMID 23006951 DOI: 10.1097/PPO.0b013e31826aef4a |
0.016 |
|
| 2013 |
Glanville N, Message SD, Walton RP, Pearson RM, Parker HL, Laza-Stanca V, Mallia P, Kebadze T, Contoli M, Kon OM, Papi A, Stanciu LA, Johnston SL, Bartlett NW. γδT cells suppress inflammation and disease during rhinovirus-induced asthma exacerbations. Mucosal Immunology. 6: 1091-100. PMID 23385428 DOI: 10.1038/mi.2013.3 |
0.016 |
|
| 2015 |
Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL, Crump M, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Stewart DA, Kahl BS, Friedberg JW, Blum KA, et al. Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era British Journal of Haematology. DOI: 10.1111/bjh.13634 |
0.016 |
|
| 2014 |
George PM, Oliver E, Dorfmuller P, Dubois OD, Reed DM, Kirkby NS, Mohamed NA, Perros F, Antigny F, Fadel E, Schreiber BE, Holmes AM, Southwood M, Hagan G, Wort SJ, ... Bartlett N, et al. Evidence for the involvement of type I interferon in pulmonary arterial hypertension. Circulation Research. 114: 677-88. PMID 24334027 DOI: 10.1161/CIRCRESAHA.114.302221 |
0.015 |
|
| 2014 |
Klein JL, Nguyen TT, Bien-Willner GA, Chen L, Foyil KV, Bartlett NL, Duncavage EJ, Hassan A, Frater JL, Kreisel F. CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma. American Journal of Clinical Pathology. 141: 381-7. PMID 24515766 DOI: 10.1309/AJCP61TLMXLSLJYS |
0.015 |
|
| 2015 |
Girkin J, Hatchwell L, Foster P, Johnston SL, Bartlett N, Collison A, Mattes J. CCL7 and IRF-7 Mediate Hallmark Inflammatory and IFN Responses following Rhinovirus 1B Infection. Journal of Immunology (Baltimore, Md. : 1950). 194: 4924-30. PMID 25847975 DOI: 10.4049/jimmunol.1401362 |
0.014 |
|
| 2015 |
Kung NH, Bartlett NL, Yaseen NR, Van Stavern GP, Bucelli RC. A Young Woman With Blurred Vision and Distal Paresthesias. Jama Neurology. 1-5. PMID 26501203 DOI: 10.1001/jamaneurol.2015.2390 |
0.014 |
|
| 2012 |
Fanale MA, Forero-Torres A, Rosenblatt JD, Advani RH, Franklin AR, Kennedy DA, Han TH, Sievers EL, Bartlett NL. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 248-55. PMID 22080439 DOI: 10.1158/1078-0432.CCR-11-1425 |
0.014 |
|
| 2014 |
Bartlett N, Garriott W, Raikhel E. What’s in the ‘Treatment Gap’? Ethnographic Perspectives on Addiction and Global Mental Health from China, Russia, and the United States Medical Anthropology: Cross Cultural Studies in Health and Illness. 33: 457-477. PMID 24417258 DOI: 10.1080/01459740.2013.877900 |
0.013 |
|
| 2014 |
Sanfilippo K, Bartlett NL. Management of Classical Hodgkin Lymphoma Cancer Consult: Expertise For Clinical Practice. 227-234. DOI: 10.1002/9781118589199.ch35 |
0.013 |
|
| 2016 |
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, et al. Diffuse large b-cell lymphoma version 1.2016: Clinical practice guidelines in oncology Jnccn Journal of the National Comprehensive Cancer Network. 14: 196-231. |
0.013 |
|
| 2011 |
Bartlett N, Xin D, Zhang H, Huang B. A qualitative evaluation of a peer-implemented overdose response pilot project in Gejiu, China. The International Journal On Drug Policy. 22: 301-5. PMID 21658931 DOI: 10.1016/J.Drugpo.2011.04.005 |
0.013 |
|
| 2011 |
Telcian AG, Laza-Stanca V, Edwards MR, Harker JA, Wang H, Bartlett NW, Mallia P, Zdrenghea MT, Kebadze T, Coyle AJ, Openshaw PJM, Stanciu LA, Johnston SL. RSV-induced bronchial epithelial cell PD-L1 expression inhibits CD8 + T cell nonspecific antiviral activity Journal of Infectious Diseases. 203: 85-94. PMID 21148500 DOI: 10.1093/infdis/jiq020 |
0.013 |
|
| 2014 |
Levy R, Ganjoo KN, Leonard JP, Vose JM, Flinn IW, Ambinder RF, Connors JM, Berinstein NL, Belch AR, Bartlett NL, Nichols C, Emmanouilides CE, Timmerman JM, Gregory SA, Link BK, et al. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1797-803. PMID 24799467 DOI: 10.1200/Jco.2012.43.9273 |
0.013 |
|
| 2011 |
Kuo C, Lim S, King NJ, Bartlett NW, Walton RP, Zhu J, Glanville N, Aniscenko J, Johnston SL, Burgess JK, Black JL, Oliver BG. Rhinovirus infection induces expression of airway remodelling factors in vitro and in vivo. Respirology (Carlton, Vic.). 16: 367-77. PMID 21199160 DOI: 10.1111/j.1440-1843.2010.01918.x |
0.013 |
|
| 2015 |
Singanayagam A, Glanville N, Bartlett N, Johnston S. Effect of fluticasone propionate on virus-induced airways inflammation and anti-viral immune responses in mice. Lancet (London, England). 385: S88. PMID 26312910 DOI: 10.1016/S0140-6736(15)60403-2 |
0.012 |
|
| 2014 |
Bartlett NL. Highlights in lymphoma from the 2013 American Society of Hematology Annual Meeting and Exposition: commentary. Clinical Advances in Hematology & Oncology : H&O. 12: 18-23. PMID 25856285 |
0.012 |
|
| 2012 |
Harris KD, Bartlett NJ, Lloyd VK. Daphnia as an emerging epigenetic model organism. Genetics Research International. 2012: 147892. PMID 22567376 DOI: 10.1155/2012/147892 |
0.012 |
|
| 2015 |
Hatchwell L, Collison A, Girkin J, Parsons K, Li J, Zhang J, Phipps S, Knight D, Bartlett NW, Johnston SL, Foster PS, Wark PA, Mattes J. Toll-like receptor 7 governs interferon and inflammatory responses to rhinovirus and is suppressed by IL-5-induced lung eosinophilia. Thorax. PMID 26108570 DOI: 10.1136/thoraxjnl-2014-205465 |
0.012 |
|
| 2014 |
Beale J, Jayaraman A, Jackson DJ, Macintyre JD, Edwards MR, Walton RP, Zhu J, Ching YM, Shamji B, Edwards M, Westwick J, Cousins DJ, Hwang YY, McKenzie A, Johnston SL, ... Bartlett NW, et al. Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation. Science Translational Medicine. 6: 256ra134. PMID 25273095 DOI: 10.1126/scitranslmed.3009124 |
0.012 |
|
| 2015 |
Forero-Torres A, Bartlett NL, Berryman RB, Chen R, Matous JV, Fanale MA, O'Connor OA, Olshefski R, Smith SE, Huebner D, Levine PL, Grove LE, Gopal AK. Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies. Leukemia & Lymphoma. 56: 1151-3. PMID 25110824 DOI: 10.3109/10428194.2014.951843 |
0.011 |
|
| 2012 |
Goyal SD, Bartlett NL. Where does brentuximab vedotin fit into the management of patients with hodgkin lymphoma? Current Hematologic Malignancy Reports. 7: 179-185. PMID 22669711 DOI: 10.1007/s11899-012-0126-1 |
0.011 |
|
| 2011 |
Vasey PL, Vanderlaan DP, Gothreau LM, Bartlett NH. Traits of separation anxiety in childhood: a retrospective study of Samoan men, women, and fa'afafine. Archives of Sexual Behavior. 40: 511-7. PMID 20013150 DOI: 10.1007/S10508-009-9589-0 |
0.011 |
|
| 2015 |
Bartlett N, Warnaar SO. Hall-Littlewood polynomials and characters of affine Lie algebras Advances in Mathematics. 285: 1066-1105. DOI: 10.1016/j.aim.2015.08.011 |
0.01 |
|
| 2014 |
McEachern LA, Bartlett NJ, Lloyd VK. Endogenously imprinted genes in Drosophila melanogaster. Molecular Genetics and Genomics : Mgg. 289: 653-73. PMID 24658702 DOI: 10.1007/s00438-014-0840-6 |
0.01 |
|
| 2013 |
Alston LL, Kratchmer C, Jeznach A, Bartlett NT, Davidson PS, Fujiwara E. Self-serving episodic memory biases: findings in the repressive coping style. Frontiers in Behavioral Neuroscience. 7: 117. PMID 24027505 DOI: 10.3389/Fnbeh.2013.00117 |
0.01 |
|
| 2015 |
Jackson DJ, Trujillo-Torralbo MB, Del-Rosario J, Bartlett N, Edwards MR, Mallia P, Walton RP, Johnston SL. The influence of asthma control on the severity of virus-induced asthma exacerbations. The Journal of Allergy and Clinical Immunology. PMID 25772596 DOI: 10.1016/j.jaci.2015.01.028 |
0.01 |
|
| 2015 |
Bartlett NW, Singanayagam A, Johnston SL. Mouse models of rhinovirus infection and airways disease. Methods in Molecular Biology (Clifton, N.J.). 1221: 181-8. PMID 25261315 DOI: 10.1007/978-1-4939-1571-2_14 |
0.01 |
|
| 2015 |
Bartlett NW, Lyau V, Raiford WA, Holland D, Gafford JB, Ellis TD, Walsh CJ. A soft robotic orthosis for wrist rehabilitation Journal of Medical Devices, Transactions of the Asme. 9. DOI: 10.1115/1.4030554 |
0.01 |
|
| 2015 |
Bartlett NW, Singanayagam A, Johnston SL. Mouse models of rhinovirus infection and airways disease Methods in Molecular Biology. 1221: 181-188. DOI: 10.1007/978-1-4939-1571-2_14 |
0.01 |
|
| 2015 |
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hoppe RT, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015 Jnccn Journal of the National Comprehensive Cancer Network. 13: 326-362. |
0.01 |
|
| 2015 |
Bartlett N. Pixel perfect Economist (United Kingdom). 411. |
0.01 |
|
| 2014 |
Jackson DJ, Makrinioti H, Rana BM, Shamji BW, Trujillo-Torralbo MB, Footitt J, Jerico Del-Rosario, Telcian AG, Nikonova A, Zhu J, Aniscenko J, Gogsadze L, Bakhsoliani E, Traub S, Dhariwal J, ... ... Bartlett NW, et al. IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. American Journal of Respiratory and Critical Care Medicine. 190: 1373-82. PMID 25350863 DOI: 10.1164/rccm.201406-1039OC |
0.01 |
|
| 2014 |
Bartlett NL. Commentary Clinical Advances in Hematology & Oncology : H&O. 12: 18-23. PMID 24870879 |
0.01 |
|
| 2014 |
Mahmutovic-Persson I, Akbarshahi H, Bartlett NW, Glanville N, Johnston SL, Brandelius A, Uller L. Inhaled dsRNA and rhinovirus evoke neutrophilic exacerbation and lung expression of thymic stromal lymphopoietin in allergic mice with established experimental asthma Allergy: European Journal of Allergy and Clinical Immunology. 69: 348-358. PMID 24283976 DOI: 10.1111/all.12329 |
0.01 |
|
| 2014 |
Tolley MT, Shepherd RF, Karpelson M, Bartlett NW, Galloway KC, Wehner M, Nunes R, Whitesides GM, Wood RJ. An untethered jumping soft robot Ieee International Conference On Intelligent Robots and Systems. 561-566. DOI: 10.1109/IROS.2014.6942615 |
0.01 |
|
| 2014 |
Bartlett N. Fighting for Breath: Living Morally and Dying of Cancer in a Chinese Village. By Anna Lora-Wainwright. Honolulu: University of Hawai‘i Press, 2013. 323 pp. $52.00 (cloth). The Journal of Asian Studies. 73: 529-530. DOI: 10.1017/S0021911814000096 |
0.01 |
|
| 2014 |
Bartlett NW, Johnston SL. Rhinoviruses Reference Module in Biomedical Research. DOI: 10.1016/B978-0-12-801238-3.02658-1 |
0.01 |
|
| 2013 |
Bartlett NL. Treatment of nodular lymphocyte-predominant hodgkinlymphoma-"do no harm" Clinical Advances in Hematology and Oncology. 11. PMID 24472810 |
0.01 |
|
| 2013 |
Nguyen TT, Kreisel FH, Frater JL, Bartlett NL. Anaplastic large-cell lymphoma with aberrant expression of multiple cytokeratins masquerading as metastatic carcinoma of unknown primary Journal of Clinical Oncology. 31: e443-e445. PMID 23775969 DOI: 10.1200/JCO.2012.46.7910 |
0.01 |
|
| 2013 |
Wang A, Treibig J, Blainey B, Wu P, Gao Y, Dalton B, Gupta D, Khan F, Bartlett N, Velichover L, Sedgwick J, Ly L. Optimizing IBM algorithmics' mark-to-future aggregation engine for real-time counterparty credit risk scoring Proceedings of Whpcf 2013: 6th Workshop On High Performance Computational Finance - Held in Conjunction With Sc 2013: the Int. Conf. For High Performance Computing, Networking, Storage and Analysis. DOI: 10.1145/2535557.2535567 |
0.01 |
|
| 2013 |
Bartlett N. Sandy's legacy in the North Atlantic - Improved tools for predicting storm surge Earth System Monitor. 19: 8-9. |
0.01 |
|
| 2012 |
Edwards MR, Bartlett NW, Hussell T, Openshaw P, Johnston SL. The microbiology of asthma Nature Reviews Microbiology. 10: 459-471. PMID 22669219 DOI: 10.1038/nrmicro2801 |
0.01 |
|
| 2012 |
Liu Y, Bartlett N, Li L, Lv X, Zhang Y, Zhou W. Attitudes and knowledge about naloxone and overdose prevention among detained drug users in Ningbo, China. Substance Abuse Treatment, Prevention, and Policy. 7: 6. PMID 22316338 DOI: 10.1186/1747-597X-7-6 |
0.01 |
|
| 2012 |
Hewson CA, Haas JJ, Bartlett NW, Message SD, Laza-Stanca V, Kebadze T, Caramori G, Zhu J, Edbrooke MR, Stanciu LA, Kon OM, Papi A, Jeffery PK, Edwards MR, Johnston SL. Rhinovirus induces MUC5AC in a human infection model and in vitro via NF-κB and EGFR pathways (European Respiratory Journal (2010) 36, (1425-1435)) European Respiratory Journal. 39: 793. DOI: 10.1183/09031936.50026910 |
0.01 |
|
| 2011 |
Wagner-Johnston ND, Bartlett NL. Role of routine imaging in lymphoma Jnccn Journal of the National Comprehensive Cancer Network. 9: 575-585. PMID 21550970 |
0.01 |
|
| 2011 |
Vasey PL, Bartlett NH. Frederick L. Whitam (1933-2009). Archives of Sexual Behavior. 40: 671-2. PMID 21544628 DOI: 10.1007/s10508-011-9775-8 |
0.01 |
|
| 2011 |
Foyil KV, Bartlett NL. Brentuximab vedotin for the treatment of CD30 + lymphomas Immunotherapy. 3: 475-485. PMID 21463188 DOI: 10.2217/imt.11.15 |
0.01 |
|
| 2011 |
Perotte A, Bartlett N, Elhadad N, Wood F. Hierarchically supervised latent Dirichlet allocation Advances in Neural Information Processing Systems 24: 25th Annual Conference On Neural Information Processing Systems 2011, Nips 2011. |
0.01 |
|
| 2010 |
Bartlett NL. The present: optimizing therapy--too much or too little? Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2010: 108-114. PMID 21239779 |
0.01 |
|
| 2010 |
Pfau D, Bartlett N, Wood F. Probabilistic deterministic infinite automata Advances in Neural Information Processing Systems 23: 24th Annual Conference On Neural Information Processing Systems 2010, Nips 2010. |
0.01 |
|
| 2002 |
Arkowitz H, Bartlett N. The Brown University Psychology Department, spring 1941: an historic photograph. Journal of the History of the Behavioral Sciences. 38: 57-60. PMID 11835221 DOI: 10.1002/Jhbs.1097 |
0.01 |
|
| Hide low-probability matches. |
